Metabotropic glutamate receptors as targets for novel antipsychotic treatments

L. J. Gray, A. J. Hannan, X. Zhang

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


In recent years metabotropic glutamate receptors have emerged as key targets for the design of new antipsychotic medications for schizophrenia, in particular mGluR5 and mGluR2/3. These receptors exhibit diverse interactions with other neurotransmitter receptors and critical elements of intracellular signalling cascades known to be important to the pharmacotherapy of schizophrenia. In addition, mGluR5 and mGluR2/3 are intimately involved in behavioural domains related to the symptoms of this disorder. Both animal and clinical studies using novel drugs targeting these receptors have provided encouraging results. The number of patents registered for drugs targeting metabotropic glutamate receptors has grown dramatically, and positive allosteric modulators for both receptors show particular promise.

Original languageEnglish
Pages (from-to)1522-1534
Number of pages13
JournalCurrent Pharmaceutical Biotechnology
Issue number8
Publication statusPublished - Jun 2012
Externally publishedYes


  • Antipsychotic
  • Metabotropic glutamate receptors
  • mGluR2
  • mGluR3
  • mGluR5
  • Schizophrenia


Dive into the research topics of 'Metabotropic glutamate receptors as targets for novel antipsychotic treatments'. Together they form a unique fingerprint.

Cite this